HPV-Associated Epigenetic Reprogramming in Oropharyngeal Squamous Cell Carcinoma: Molecular Mechanisms, Circulating Biomarkers and Clinical Translation
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has become the dominant form of oropharyngeal cancer in many high-income countries and is now recognised as a biologically and clinically distinct entity with markedly better survival than its tobacco-related counterpart. Beyond the canonical inactivation of p53 and pRb by the viral oncoproteins E6 and E7, HPV profoundly remodels the host and viral epigenomes. HPV-positive tumours display a hypermethylated landscape, including a CpG island methylator-like phenotype that targets Polycomb repressive complex 2 genes, alongside altered histone-modifying activity, chromatin remodelling and deregulated non-coding RNA networks. Methylation of the viral genome itself, particularly of the upstream regulatory region and E2 binding sites, tracks with integration and oncogene expression. These changes shape the tumour immune microenvironment and treatment response. They also leave traces in the circulation: circulating tumour HPV DNA, methylated cell-free DNA and extracellular-vesicle microRNAs are emerging as tools for diagnosis, risk stratification and post-treatment surveillance. This review summarises current knowledge of HPV-driven epi-genetic reprogramming in OPSCC, evaluates the analytical and clinical validity of epigenetic and viral liquid-biopsy biomarkers, and discusses their translation into treatment de-escalation, epigenetic therapy, immunotherapy com-binations and nutri-epigenetic modulation.
Authors
- Stavros Derdas (ORCID: https://orcid.org/0000-0003-3725-3282)
Publication Details
- Journal
- Preprints.org
- Published
- 2026-11-18
- DOI
- https://doi.org/10.20944/preprints202611.1822.v1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- preprint